SCHEMBL17325906

SCHEMBL17325906

COc1cnc(C(N)=O)c(N)n1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.51
NNMT P40261 5/20 0.46
ALDH1A1 P00352 2/20 0.42
GAA P10253 2/20 0.42
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
PLAU P00749 5/20 0.40
PDPK1 O15530 1/20 0.40
POLB P06746 1/20 0.39
BACE1 P56817 1/20 0.39
IKBKB O14920 2/20 0.38
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
HPGDS O60760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360918 0.86 SIRT6 (0.47) SIRT6NNMTALDH1A1MKNK1MKNK2
SCHEMBL361309 0.84 NPSR1 (0.45) SIRT6NNMTALDH1A1GAAPLAU
SCHEMBL15995001 0.82 NNMT (0.53) SIRT6NNMTALDH1A1GAAMKNK1
SCHEMBL28642566 0.82 SIRT6 (0.51) SIRT6NNMTALDH1A1GAAMKNK1
SCHEMBL17954281 0.81 SIRT6 (0.50) SIRT6NNMTALDH1A1GAAMKNK1
SCHEMBL28644569 0.79 SIRT6 (0.51) SIRT6NNMTALDH1A1GAAMKNK1
SCHEMBL14471555 0.77 PDPK1 (0.45) NNMTALDH1A1PLAUPDPK1KDM4E
SCHEMBL18779089 0.76 PDPK1 (0.44) NNMTALDH1A1PLAUPDPK1POLB
SCHEMBL4253359 0.75 NPSR1 (0.47) SIRT6NNMTALDH1A1GAAKDM4E
SCHEMBL4253183 0.75 SIRT6 (0.47) SIRT6NNMTALDH1A1PLAUPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148996-B1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2021-05-05 EP disclosed
US-9732088-B2 C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2017-08-15 US disclosed
US-20170114065-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-04-27 US disclosed
WO-2016118404-A1 IMINOTHIADIAZINE DIOXIDES BEARING AN AMINE-LINKED SUBSTITUENT AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-07-28 WO disclosed
WO-2015187437-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114065-A1 C2-CARBOCYCLIC IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE2, BACE1, APP SIRT6 3121/4885NNMT 550/4885ALDH1A1 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.